(Reuters) -Johnson & Johnson said on Monday it has discontinued a late-stage study testing its experimental drug to treat a ...

Researchers are a step closer to revolutionizing how doctors use radiotherapy to treat patients with muscle-invasive bladder ...

Transurethral resection should be done, but this procedure is prone to both overestimating and underestimating staging ... the diagnosis and treatment of Ta and T1 bladder cancer.

Researchers are a step closer to revolutionising how doctors use radiotherapy to treat patients with muscle-invasive bladder ...

Pharma stock Theralase Technologies (TSXV:TLT) announced a significant update on its ongoing bladder cancer clinical study ...

Urological malignancies, encompassing bladder cancer, prostate cancer, kidney cancer, and others, are among the most ...

In response to the FDA request, there is a demonstrated duration of CR of 13.2% (9/68) at 540 days, 8.8% (6/68) at 630 days, 7.4% (5/68) at 720 days, 7.4% (5/68) at 900 days and 5.9% (4/68) at 1080 ...

Health secretary Wes Streeting has announced a series of health investments, including a new blood test that can detect ...

Cancer is a devastating diagnosis received by about 1300 Northlanders each year. Northern Advocate health reporter Denise ...

We randomly assigned, in a 1:1 ratio, patients with localized muscle-invasive bladder cancer of clinical stage T2 (confined ... plans to start adjuvant treatment. The estimated 5-year disease ...

Northwestern raised a record $1.05 billion in research funding this fiscal year, a 5% increase since 2023. The Daily compiled ...

It is the first of a slew of cancer drugs to now funded by Pharmac following the agency's multi-million dollar budget boost.